We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 925.00 | 924.50 | 925.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCLIN
RNS Number : 7553C
Clinigen Group plc
02 October 2018
2 October 2018
Clinigen Group plc
Clinigen Group Completes Acquisition of CSM
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, today announces that it has completed the acquisition of CSM Parent, Inc. ('CSM'), which was announced on 27 September 2018 (the "Acquisition").
Following Admission of the Placing Shares on 1 October 2018 (details of the Placing having been announced by the Company on 27 September 2018 to coincide with the announcement of the Acquisition), the Company now has in issue 131,949,754 ordinary shares of 0.1p each, with voting rights. Clinigen does not hold any shares in treasury. This figure of 131,949,754 ordinary shares may be used by shareholders in Clinigen to determine if they are required to notify their interest in, or a change in their interest in, Clinigen under the Financial Conduct Authority's Disclosure and Transparency Rules.
For further information, please contact:
Clinigen Group plc Tel:+44 (0) 1283 495 010 Shaun Chilton, Group Chief Executive Martin Abell, Group Chief Financial Officer Matt Parrish, Head of Investor Relations Numis Securities Limited (Nominated Tel: +44 (0)20 7260 1000 Adviser, Joint Financial Adviser and Joint Corporate Broker to Clinigen) Michael Meade James Black Freddie Barnfield RBC Capital Markets (Joint Financial Tel: +44 (0)20 7653 4000 Adviser and Joint Corporate Broker to Clinigen) Marcus Jackson Thomas Stockman Elliot Thomas Instinctif Partners (FPR Adviser Tel: +44 (0)20 7457 2020 to Clinigen) Adrian Duffield Melanie Toyne Sewell Alex Shaw
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.
For more information, please visit www.clinigengroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ACQFKBDPPBDDFKK
(END) Dow Jones Newswires
October 02, 2018 11:59 ET (15:59 GMT)
1 Year Clinigen Chart |
1 Month Clinigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions